Should We Be Cautious About Integra LifeSciences Holdings Corporation's (NASDAQ:IART) ROE Of 1.5%?
Integra LifeSciences Holdings (NASDAQ:IART) Stock Falls 9.0% in Past Week as Three-year Earnings and Shareholder Returns Continue Downward Trend
Wells Fargo Downgrades Integra Lifesciences(IART.US) to Hold Rating, Cuts Target Price to $25
Integra Lifesciences: Hold Rating Amidst Compliance Challenges and Revenue Impact With a Long-Term Recovery Outlook
Integra LifeSciences to Present at the 2024 Wells Fargo Healthcare Conference
BTIG Maintains Integra Lifesciences(IART.US) With Sell Rating, Maintains Target Price $20
BTIG Maintains Integra Lifesciences(IART.US) With Sell Rating, Cuts Target Price to $20
Bullish Integra LifeSciences Holdings Insiders Loaded Up On US$2.50m Of Stock
Integra LifeSciences Is Maintained at Sell by Citigroup
Expert Outlook: Integra Lifesciences Through The Eyes Of 8 Analysts
Express News | Integra Lifesciences Holdings Corp : Citigroup Cuts Target Price to $20 From $23
Citi Maintains Integra Lifesciences(IART.US) With Sell Rating, Cuts Target Price to $20
Integra LifeSciences Continues to Make Progress on Its ESG Strategy
Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Potentially Undervalued?
Integra LifeSciences Holdings Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Integra's (IART) Q2 Earnings and Revenues Top, Margins Down
Integra LifeSciences Analysts Cut Their Forecasts After Q2 Results
JMP Securities Maintains Market Outperform on Integra Lifesciences, Lowers Price Target to $35
Morgan Stanley Maintains Integra Lifesciences(IART.US) With Sell Rating, Cuts Target Price to $25
A Quick Look at Today's Ratings for Integra Lifesciences(IART.US), With a Forecast Between $22 to $35
No Data
No Data